To The Moon

The e-commerce growth stock is on sale. Few growth stocks have been hit as hard in the market sell-off as Shopify. Shares of the e-commerce software leader have plunged 80% in just six months as a combination of shifting market sentiment, slowing growth in e-commerce, and declining valuations in the software-as-a-service sector have all shredded the stock. Even after that plunge, it's still hard to call Shopify cheap. It trades at a price-to-sales ratio of 7 based on trailing results, and its price-to-earnings ratio is well into the triple digits. But buying Shopify could prove to be a smart move down the road. Here are three reasons you should take advantage of the discount. 1. The stock is below pre-pandemic levels Anchoring in the stock market (when you use a previous price to put the c

looking at TSA figures, 1st 9 days of May is up 17% from last mth! Sentiment negative, fear & liquidity/margin calls causing lots of downside.. If travel growth continues at this rate $V will benefit greatly$Visa(V)$

Big data and analytics player Palantir Technologies $Palantir Technologies Inc.(PLTR)$ stock fell by over 20% in Monday’s trading after the company published a mixed set of Q1 2022 results, with its outlook for Q2 also falling short of estimates. While quarterly revenues were better than expected, rising 31% versus last year to $446 million, adjusted earnings came in at $0.02 per share, missing estimates. While the commercial business continued to fare well, with revenue rising 54% to $205 million, driven by growth in the U.S., investors appear to be concerned about a slowdown in Palantir’s government business, which saw sales rise just about 16% year-over-year to $242 million, marking a slowdown from 80% plus growth levels in Q1 2021. For Q2, the co

Still buying up dips. I expect the earnings to be exactly what we expect; High growth in sales, and R&D spend that's in line. If you want to put your money in dying companies with zero growth that's your choice, I prefer to invest in companies that will actually grow sales...$Unity Software Inc.(U)$

$Starbucks(SBUX)$ Starbucks Corporation SBUX is scheduled to report second-quarter fiscal 2022 results on May 3, after the closing bell. In the last reported quarter, the company delivered an earnings miss of 10%. Q2 Estimates The Zacks Consensus Estimate for fiscal second-quarter earnings is pegged at 60 cents per share, indicating a decline of 3.2% year over year. In the past seven days, earnings estimates for the current quarter have remained stable. The consensus mark for revenues stands at $7.61 billion, suggesting growth of 14.1% from the year-ago quarter. The company’s fiscal second-quarter performance is likely to have benefited from robust comps growth and digitalization. Increase in transaction and average ticket growth might have favored c

$DBS GROUP HOLDINGS LTD(D05.SI)$ DBS’s about-face decision on a retail crypto exchange – canceling its plans to open one by the end of 2022 – leaves us with two questions: Is this another chapter in Singapore’s continued tightening of crypto regulations? And will this stymie OSL, the Hong Kong-based institutional exchange that provides DBS with exchange software? The answer to both is, not really. It’s not a secret that authorities in Singapore aren’t fans of retail crypto trading. Earlier this year, regulators banned direct-to-consumer marketing for exchanges and told crypto ATM operators to turn off their machines. It also put DeFiance Capital, one of the larger crypto funds in the city-state, on an investor alert list because it was “wrongly pe

$Micron Technology(MU)$ Automobile Recovery Global light vehicle unit sales are transitioning from ICE (internal combustion engine) to EV (electric vehicles). Chart 1 shows that the QoQ change in the past three quarters of 2021 of BEV (battery EV) shipments was significantly greater than overall automobile shipments. Chart 1 (The Information Network) Chart 2 shows that BEV + PHEV (plug-in hybrid vehicle) total light vehicle sales recovering by only 4.6% from the crisis year of 2020, the 108% growth of EVs means doubling their market share. (Chart 2) EV Volumes Automobile Semiconductor Growth Not only are vehicle shipments and revenue recovering, but more semiconductors are being used each year, as shown in Chart 3, according to The Information Networ

If you've been sitting on the sidelines, you have a huge opportunity to buy. Machine trading is absolutely destroying the market. For the past 8 months, it has gotten worse with triggers set to dump shares across the board, no matter the sector. NFLX drops and the entire market gets sold off at the bell. This isn't retail investors, this is all triggered by algo/bots reacting. Stocks like and $NIO Inc.(NIO)$ have nothing to do with NFLX, and they were both up in premarket, but the institutions took advantage to get prices down. There's absolutely no news to cause $XPeng Inc.(XPEV)$ and NIO to drop 7% right now...only price manipulation. Longs have no choice to continue riding through this storm and others take a

Sean Gallup/Getty Images News An unprecedented emphasis has been placed on outpacing inflation. The repercussions of inflation outpacing wage growth and the return on invested capital have detrimental ramifications. If earned income or the return of capital from investments doesn't keep pace with rising prices and escalated costs of living, inflation can significantly decrease purchasing power, which could correlate to depleting savings accounts, retirement portfolios, or increased debt levels. The impacts of rampant inflation can become catastrophic unless an individual is well hedged in a portfolio allocation that can outpace inflation.Today inflation has accelerated to 8.5%, which is the highest level on record since December of 1981. Energy prices increased 32%, while food prices jumpe

Some shorts are drawing parallels between Sabizabulin and Lorenlimab following a recently published misleading article by Chris Sandburg in IF. It’s not even an apples to Orange comparison ! This is why.. In March, CytoDyn Leronlimab's Phase III trial, a CCR5 antagonist, failed to hit the primary endpoint of reducing symptoms and missed all secondary endpoints, including if the drug decreased mortality for COVID-19. However, the company placed a positive spin, focusing on a subgroup of 62 patients on mechanical ventilation, arguing that leronlimab caused a 24% decrease in all-cause mortality and a six-day reduction in hospitalization. They then released a second press announcement describing an “age adjustment” analysis alleging leronlimab decreased mortality in older patients. The FDA sta